Skip to main content

14 Result(s)

within E Jost Remove this filter Oncology Remove this filter

and

  1. Article

    Sollen Kinder onkologischer Patienten während der COVID-19-Pandemie Kitas oder Schulen besuchen?

    R. Bremen, Dr. med. A. Petermann-Meyer, N. Ernstmann, E. Jost, J. Panse… in Der Onkologe (2021)

    Download PDF (465 KB) View Article

  2. Article

    Open Access

    Erratum: DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

    Correction to: Oncogene (2016) 35, 3079–3082; doi:10.1038/onc.2015.359; published online 5 October 2015 Updated online 13 March 2017: This article was originally published under a CC BY-NC-ND 4.0 license, but ...

    H J Ferreira, H Heyn, M Vizoso, C Moutinho, E Vidal, A Gomez, A Martínez-Cardús… in Oncogene (2017)

    Download PDF (98 KB) View Article

  3. No Access

    Article

    Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

    Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is repor...

    R F Schlenk, F Stegelmann, A Reiter, E Jost, N Gattermann, H Hebart, C Waller… in Leukemia (2017)

  4. No Access

    Article

    Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians

    Philadelphia-negative myeloproliferative neoplasms (MPN) comprise a heterogeneous group of chronic hematological malignancies with significant variations in clinical characteristics. Due to the long survival a...

    A. Kaifie, S. Isfort, N. Gattermann, W. Hollburg, M. Klausmann… in Annals of Hematology (2016)

  5. Article

    Open Access

    DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

    Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifi...

    H J Ferreira, H Heyn, M Vizoso, C Moutinho, E Vidal, A Gomez, A Martínez-Cardús… in Oncogene (2016)

    Download PDF (1730 KB) View Article

  6. Article

    Open Access

    Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

    Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at increased risk for thrombosis/thromboemboli...

    A. Kaifie, M. Kirschner, D. Wolf, C. Maintz, M. Hänel… in Journal of Hematology & Oncology (2016)

    Download PDF (593 KB) View Article

  7. Article

    Open Access

    Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia

    Mutations in the genetic sequence of the DNA de novo methyltransferase DNMT3A (DNA methyltransferase 3A) are found in many patients with acute myeloid leukemia (AML). They lead to dysfunction of DNMT3A protein an...

    E Jost, Q Lin, C I Weidner, S Wilop, M Hoffmann, T Walenda, M Schemionek… in Leukemia (2014)

    Download PDF (2452 KB) View Article

  8. No Access

    Article

    Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR–ABL-positive cells

    Persistent activation of the Abl tyrosine kinase in the BCR–ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR–ABL phosphorylates STAT5 and Src family kina...

    N Chatain, P Ziegler, D Fahrenkamp, E Jost, R Moriggl, H Schmitz-Van de Leur… in Oncogene (2013)

  9. Article

    Open Access

    Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53

    Malignant melanomas are highly resistant to chemotherapy. First-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (DTIC) and temozolomide (TMZ) and the chloroethylating age...

    S C Naumann, W P Roos, E Jöst, C Belohlavek, V Lennerz… in British Journal of Cancer (2009)

    Download PDF (640 KB) View Article

  10. No Access

    Article

    SOCS2: inhibitor of JAK2V617F-mediated signal transduction

    Janus kinase 2 (JAK2)V617F-activating mutations (JAK2mu) occur in myeloproliferative disorders (MPDs) and myelodysplastic syndromes (MDSs). Cell lines MB-02, MUTZ-8, SET-2 and UKE-1 carry JAK2V617F and derive fro...

    H Quentmeier, R Geffers, E Jost, R A F MacLeod, S Nagel, S Röhrs, J Romani… in Leukemia (2008)

  11. No Access

    Article

    Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders

    An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands wit...

    E Jost, N do Ó, E Dahl, C E Maintz, P Jousten, L Habets, S Wilop, J G Herman… in Leukemia (2007)

  12. No Access

    Article

    DNA methylation changes in multiple myeloma

    Using a candidate gene approach, we analyzed the methylation status of the promoter-associated CpG islands of 11 well-characterized tumor suppressor genes by methylation-specific polymerase chain reaction in f...

    O Galm, S Wilop, J Reichelt, E Jost, G Gehbauer, J G Herman, R Osieka in Leukemia (2004)

  13. No Access

    Article

    Complex karyotype and absence of mutation in the c-kit receptor in aggressive mastocytosis presenting with pelvic osteolysis, eosinophilia and brain damage

    Aggressive mastocytosis is a form of systemic mast cell disease (SMCD) characterized by organ infiltration, bone lesions, eosinophilia and lymphadenopathies. Here we report a patient with unusual clinical fea...

    E. Jost, L. Michaux, M. Vanden Abeele, B. Boland, D. Latinne… in Annals of Hematology (2001)

  14. No Access

    Article

    Remission of severe cold agglutinin disease Rituximab therapy

    N Layios, E Van Den Neste, E Jost, V Deneys, JM Scheiff, A Ferrant in Leukemia (2001)